Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinghai Univ. Rac1 compound Ano-6: sourced facts only. name: "A pull-down assay revealed that the interaction between Rac1 and its downstream effector protein PAK1 was inhibited by these compounds and that the compound Ano-6 exhibited substantial activity, with an inhibition rate of more than 90 %." [PMID:38833990]; target: "A pull-down assay revealed that the interaction between Rac1 and its downstream effector protein PAK1 was inhibited by these compounds and that the compound Ano-6 exhibited substantial activity, with an inhibition rate of more than 90 %." [PMID:38833990]; developer: "State Key Laboratory of Plateau Ecology and Agriculture, Qinghai University, 251 Ningda Road, Xining 810016, Qinghai, China; Department of Pharmacy, Medical College of Qinghai University, 16 Kunlun Road, Xining 810016, Qinghai, China." [PMID:38833990]; stage: "Four weeks of oral treatment with Ano-6 was well-tolerated in mice, and it induced a potential anti-tumour response in xenografts of MDA-MB-231 cells." [PMID:38833990]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinghai Univ. Rac1 compound Ano-6.